AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17561795 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily glargine (GL)
Number of subjects: 30
Study 17561795 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily 70/30 aspart premix
Number of subjects: 30
Study 16082602 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 2741
Study 16082602 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple end point (all-cause death, recurrent myocardial infarction, recurrent angina)
Number of subjects: 2741
Study 16082602 — intervention group
Group type: COMPARATOR
Intervention: Not receiving reperfusion therapy
Number of subjects: 2741
Study 16082602 — intervention group
Group type: COMPARATOR
Intervention: Death
Number of subjects: 2741
Study 11990874 — intervention group
Group type: EXPERIMENTAL
Intervention: MS‐ET (exercise training)
Number of subjects: 26
Study 11990874 — intervention group
Group type: COMPARATOR
Intervention: MS‐NI (nontraining)
Number of subjects: 26
Study 11990874 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 26
Study 11990874 — intervention group
Group type: COMPARATOR
Intervention: All groups (MS‐ET, MS‐NI, Control)
Number of subjects: 26
Study 10456206 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance test in the morning (0830 h)
Number of subjects: 9
Study 10456206 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance test in the evening (2030 h)
Number of subjects: 9
Study 10456206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting NEFA levels in the morning
Number of subjects: 9
Study 10456206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting NEFA levels in the evening
Number of subjects: 9
Study 10456206 — intervention group
Group type: EXPERIMENTAL
Intervention: NEFA response to insulin in the morning
Number of subjects: 9
Study 10456206 — intervention group
Group type: EXPERIMENTAL
Intervention: NEFA response to insulin in the evening
Number of subjects: 9
Study 8642805 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine (1‐2 mg/day)
Number of subjects: 12
Study 8642805 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50‐100 mg/day)
Number of subjects: 12
Study 2144797 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion (50 ng/kg/min)
Number of subjects: 13
Study 2144797 — intervention group
Group type: COMPARATOR
Intervention: Converting enzyme inhibitor (CEI) enalapril (20 mg p.o. for 5 days)
Number of subjects: 13
Study 2144797 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (placebo)
Number of subjects: 13
Study 7004678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 38
Study 7004678 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 38
Study 7004678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29589410 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistation exercise program (2 times/week for 6 weeks)
Number of subjects: 34
Study 29589410 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued regular training routines)
Number of subjects: 34
Study 29589410 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 34
Study 29589410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 28261426 — intervention group
Group type: EXPERIMENTAL
Intervention: QuikClot Combat Gauze (QCG)
Number of subjects: 60
Study 28261426 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze
Number of subjects: 60
Study 25927452 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored stroke education films (one in English and one in Spanish)
Number of subjects: 250
Study 25927452 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 250
Study 23376868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study 23376868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21047568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (3 times 40 mg at 0 hr, 24 hr, and 48 hr)
Number of subjects: 60
Study 21047568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg at 0 hr) plus placebo (24 hr and 48 hr)
Number of subjects: 60
Study 21047568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 hr, 24 hr and 48 hr)
Number of subjects: 60
Study 19274640 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine treatment
Number of subjects: 6
Study 19274640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 17315136 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 672
Study 17315136 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h post-load glucose
Number of subjects: 672
Study 17315136 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h post-load glucose
Number of subjects: 672
Study 17315136 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose, 1-h post-load glucose, 2-h post-load glucose
Number of subjects: 672
Study 14722173 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 2%
Number of subjects: 0
Study 14722173 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine/lidocaine
Number of subjects: 0
Study 12408169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 54
Study 9587121 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging system based on risk score
Number of subjects: 1441
Study 9587121 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging system based on calculated volume of prostate carcinoma and PSA (cVCa-PSA)
Number of subjects: 1441
Study 7843867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha-Yoga exercise
Number of subjects: 0
Study 7843867 — intervention group
Group type: COMPARATOR
Intervention: Control group (reading in a comfortable position)
Number of subjects: 0
Study 2974934 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine + fenoterol + ipratropium bromide
Number of subjects: 11
Study 2974934 — intervention group
Group type: COMPARATOR
Intervention: nicardipine + fenoterol
Number of subjects: 11
Study 29962176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10 supplementation for 6 weeks
Number of subjects: 16
Study 29962176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27521177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox maze IV procedure (CMP‐IV), n = 60
Number of subjects: 120
Study 27521177 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cox maze IV procedure (MCMP‐IV), n = 60
Number of subjects: 120
Study 27521177 — intervention group
Group type: COMPARATOR
Intervention: Modified Cox maze IV procedure (MCMP‐IV)
Number of subjects: 120
Study 27521177 — intervention group
Group type: COMPARATOR
Intervention: Cox maze IV procedure (CMP‐IV)
Number of subjects: 120
Study 25791056 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive thermal mattress (CTM)
Number of subjects: 160
Study 25791056 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 160
Study 23357887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral skills program focused on decision making and substance use, duration not specified.
Number of subjects: 243
Study 23357887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral skills program
Number of subjects: 243
Study 20010551 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 27
Study 20010551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 18328724 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump (group A)
Number of subjects: 20
Study 18328724 — intervention group
Group type: COMPARATOR
Intervention: On-pump (group B)
Number of subjects: 20
Study 15848261 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 26
Study 15848261 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy combined with standing balance training by biofeedback (BPM Monitor)
Number of subjects: 26
Study 12585949 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (3.125 mg twice daily, uptitrated to 25 mg twice daily)
Number of subjects: 2289
Study 12585949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2289
Study 10565463 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF glycine levels in newborns with moderate HIE (19.1 micromol/l)
Number of subjects: 48
Study 10565463 — intervention group
Group type: COMPARATOR
Intervention: CSF glycine levels in control group (12.08 micromol/l)
Number of subjects: 48
Study 10565463 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF glycine levels in newborns without HIE (12.49 micromol/l)
Number of subjects: 48
Study 10565463 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF glycine levels in newborns with mild HIE (12.14 micromol/l)
Number of subjects: 48
Study 8984864 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 1 mg
Number of subjects: 0
Study 8984864 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine 30 micrograms
Number of subjects: 0
Study 8984864 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 0
Study 2015476 — intervention group
Group type: COMPARATOR
Intervention: Varicose veins without complications
Number of subjects: 14
Study 2015476 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicose veins with lipodermatosclerosis
Number of subjects: 14
Study 2015476 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicose veins with a history of ulceration
Number of subjects: 14
Study 2015476 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising venous pressure for 30 min
Number of subjects: 14
Study 500575 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylidrin HCL
Number of subjects: 60
Study 500575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31918168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 58
Study 31918168 — intervention group
Group type: COMPARATOR
Intervention: Thinking-as-usual control
Number of subjects: 58
Study 31010345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine misoprostol 800 µg with oxytocin (group A)
Number of subjects: 160
Study 31010345 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin alone (group B)
Number of subjects: 160
Study 28449402 — intervention group
Group type: EXPERIMENTAL
Intervention: lixisenatide 20 µg
Number of subjects: 35
Study 28449402 — intervention group
Group type: COMPARATOR
Intervention: insulin-glulisine (iGlu)
Number of subjects: 35
Study 26030788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 400 IU/day
Number of subjects: 32
Study 26030788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 800 IU/day
Number of subjects: 32
Study 26030788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 32
Study 26030788 — intervention group
Group type: COMPARATOR
Intervention: Free vitamin D levels at birth
Number of subjects: 32
Study 23870608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of ASA 100 mg and clopidogrel 75 mg
Number of subjects: 64
Study 23870608 — intervention group
Group type: COMPARATOR
Intervention: Free combination of ASA and clopidogrel
Number of subjects: 64
Study 23870608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (fixed-dose and free combination)
Number of subjects: 64
Study 21898310 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention programme (watchful waiting, bibliotherapy, problem-solving treatment, re-referral to primary care)
Number of subjects: 170
Study 21898310 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study 19109835 — intervention group
Group type: EXPERIMENTAL
Intervention: CUSA with radiofrequency coagulator (TissueLink)
Number of subjects: 24
Study 19109835 — intervention group
Group type: COMPARATOR
Intervention: CUSA with bipolar cautery
Number of subjects: 24
Study 19109835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 17898401 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin plus dexamethasone (800 mg gabapentin and 8 mg dexamethasone IV)
Number of subjects: 80
Study 17898401 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (800 mg)
Number of subjects: 80
Study 17898401 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (8 mg)
Number of subjects: 80
Study 17898401 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80
Study 14978608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (protocol applied)
Number of subjects: 298
Study 14978608 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 298
Study 11533837 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg per day of oral iron
Number of subjects: 30
Study 11533837 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/kg per day of oral iron
Number of subjects: 30
Study 11533837 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both doses (8 mg/kg vs 16 mg/kg)
Number of subjects: 30
Study 9934543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 50 mg/kg twice-daily (n = 130)
Number of subjects: 258
Study 9934543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 33.3 mg/kg three-times-daily (n = 128)
Number of subjects: 258
Study 8109809 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol delivered from a metered dose inhaler (MDI)
Number of subjects: 20
Study 8109809 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol delivered from a novel multiple dose powder inhaler (MDPI) Easyhaler
Number of subjects: 20
Study 8109809 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 20
Study 8109809 — intervention group
Group type: EXPERIMENTAL
Intervention: MDPI actuated during inhalation
Number of subjects: 20
Study 8109809 — intervention group
Group type: EXPERIMENTAL
Intervention: MDPI released before inhalation
Number of subjects: 20
Study 8109809 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI and MDPI
Number of subjects: 20
Study 3287996 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 25 micrograms q.i.d.
Number of subjects: 18
Study 3287996 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 micrograms q.i.d.
Number of subjects: 18
Study 3287996 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms q.i.d.
Number of subjects: 18
Study 3287996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31037343 — intervention group
Group type: EXPERIMENTAL
Intervention: P11-4
Number of subjects: 37
Study 31037343 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish
Number of subjects: 37
Study 29718314 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (no-RT)
Number of subjects: 0
Study 29718314 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 0
Study 28296582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated RT (60 Gy in 20 fractions over 4 weeks)
Number of subjects: 1206
Study 28296582 — intervention group
Group type: COMPARATOR
Intervention: Conventional RT (78 Gy in 39 fractions over 8 weeks)
Number of subjects: 1206
Study 28296582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated RT
Number of subjects: 1206
Study 28296582 — intervention group
Group type: COMPARATOR
Intervention: Conventional RT
Number of subjects: 1206
Study 28296582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 1206
Study 25946929 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU of oral vitamin D per month for 6 months
Number of subjects: 88
Study 25946929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 22770481 — intervention group
Group type: EXPERIMENTAL
Intervention: Halogen bleaching (38% hydrogen peroxide, 8 minutes)
Number of subjects: 60
Study 22770481 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser bleaching (38% hydrogen peroxide, 30 seconds)
Number of subjects: 60
Study 22770481 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical activation only (38% hydrogen peroxide)
Number of subjects: 60
Study 22770481 — intervention group
Group type: EXPERIMENTAL
Intervention: Halogen bleaching
Number of subjects: 60
Study 22770481 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser and chemical activation
Number of subjects: 60
Study 21467234 — intervention group
Group type: EXPERIMENTAL
Intervention: rs6497287 genetic variant on 15q13
Number of subjects: 202
Study 21467234 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3774315 genetic variant on 3q26
Number of subjects: 202
Study 18809783 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma arc light (Ortho LITE, 3M Unitek)
Number of subjects: 43
Study 18809783 — intervention group
Group type: COMPARATOR
Intervention: Conventional tungsten-quartz halogen curing light (Visilux 2, 3M Unitek)
Number of subjects: 43
Study 17919621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 90
Study 17919621 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 90
Study 15201943 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (interleukin-1 receptor antagonist)
Number of subjects: 2932
Study 15201943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2932
Study 11535498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative SCT (fludarabine/cyclophosphamide conditioning)
Number of subjects: 14
Study 11535498 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative SCT (cyclophosphamide/high-dose total body irradiation)
Number of subjects: 14
Study 9573752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin‐Releasing Hormone analogue (two injections monthly)
Number of subjects: 60
Study 9573752 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 60
Study 7530724 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal levonorgestrel (Norplant) users
Number of subjects: 0
Study 7530724 — intervention group
Group type: COMPARATOR
Intervention: Normally cycling women
Number of subjects: 0
Study 2899773 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride 25 mg twice daily plus elemental calcium 1 g daily and a vitamin D2 supplement
Number of subjects: 257
Study 2899773 — intervention group
Group type: COMPARATOR
Intervention: Alternative therapies usually prescribed in France
Number of subjects: 257
Study 31017912 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item USDA Adult Food Security Survey Module (FSSM) with the 2-item food sufficiency screener
Number of subjects: 462
Study 31017912 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-item food sufficiency screener
Number of subjects: 462
Study 31017912 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item FSSM
Number of subjects: 462
Study 28228452 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid
Number of subjects: 155
Study 28228452 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative care
Number of subjects: 155
Study 26729437 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus triptorelin
Number of subjects: 116
Study 26729437 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus triptorelin
Number of subjects: 116
Study 24814037 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g red ginseng daily for 12 weeks
Number of subjects: 82
Study 24814037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 22705480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group
Number of subjects: 34
Study 22705480 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation group
Number of subjects: 34
Study 19995506 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Fissurit sealants applied using a single bottle adhesive system (One-step prior to sealant application)
Number of subjects: 54
Study 19995506 — intervention group
Group type: COMPARATOR
Intervention: Group B: Sealants applied using the conventional etch and seal technique
Number of subjects: 54
Study 17322147 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxybutynin (15 mg once daily for 5 days)
Number of subjects: 18
Study 17322147 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxybutynin (5 mg every 8 hours for 5 days)
Number of subjects: 18
Study 15660119 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) increase of 10 mmHg
Number of subjects: 9338
Study 15660119 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 9338
Study 11986206 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (300 to 1000 mg per day)
Number of subjects: 75
Study 11986206 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 75
Study 11986206 — intervention group
Group type: COMPARATOR
Intervention: Standard cytarabine-based therapy
Number of subjects: 75
Study 9719109 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiation therapy plus temporary stereotactic iodine-125 implants delivering a minimum peripheral tumor dose of 60 Gy
Number of subjects: 140
Study 9719109 — intervention group
Group type: COMPARATOR
Intervention: External radiation therapy only delivering 50 Gray (Gy) in 25 fractions over 5 weeks
Number of subjects: 140
Study 9719109 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization to the implant arm
Number of subjects: 140
Study 9719109 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy or reoperation at recurrence
Number of subjects: 140
Study 9719109 — intervention group
Group type: EXPERIMENTAL
Intervention: KPS > or =90
Number of subjects: 140
Study 8083913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential gradient pneumatic leg compression (SCD)
Number of subjects: 400
Study 8083913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin (H)
Number of subjects: 400
Study 8083913 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 400